Indications for: Raxibacumab
Treatment of inhalational anthrax in combination with appropriate antibacterial drugs. Prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Limitations of Use:
Has no direct antibacterial activity. Does not cross the blood-brain barrier. Does not prevent or treat meningitis. Pediatrics: safety and pharmacokinetics were not studied.
See full labeling. Premedicate with diphenhydramine (oral or IV) within 1hr prior to raxibacumab infusion. Give as IV infusion over 135mins. 40mg/kg.
See full labeling. Premedicate with diphenhydramine (oral or IV) within 1hr prior to raxibacumab infusion. Give as IV infusion over 135mins. ≤10kg: 80mg/kg. >10–40kg: 60mg/kg. >40kg: 40mg/kg.
Hypersensitivity and anaphylaxis.
Have resuscitative equipment and medication readily available. Monitor infusion during and after administration. Interrupt or discontinue if hypersensitivity reactions or anaphylaxis occur; treat appropriately. Pregnancy. Nursing mothers.
Rash, pain in extremity, pruritus, somnolence.
Generic Drug Availability:
Single-use vial (34mL)—1